Compare Dover Corp (DOV) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dover Corp vs ResMed Inc. — how do they compare? Dover Corp trades at $188.84 (market cap $25.45B), while ResMed Inc. trades at $230.12 (market cap $31.89B). The key difference: ResMed Inc. is the larger of the two by market cap, and ResMed Inc. pays the higher dividend (1.16%). Which is the better fit depends on your goals — on Pluang, investors hold Dover Corp for 73 Days and ResMed Inc. for 51 Days on average.
| DOV | RMD | |
|---|---|---|
Market Cap | $25.45B | $31.89B |
Volume | 661,758 | 618,314 |
Sector | Industrials | Health |
52-Week High | $233.31 | $277.88 |
52-Week Low | $161.16 | $182.82 |
Typical Hold Time | 73 Days | 51 Days |
Enterprise Value | $26.95B | $31.24B |
Dividend Yield | 1.11% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOV trades at $189.32, up 0.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported consistent earnings beats in recent quarters, with Q3 2026 results pending. Revenue for 2025 was $8.09B, with a net income margin of 13.48%, while analyst consensus is strongly positive with a $243.20 price target. Recent news highlights product launches and strategic acquisitions, such as the completion of the Cloeren acquisition in August 2026.
DOV presents a favorable fundamental outlook with solid profitability and analyst support, though technical indicators suggest near-term caution. Upside potential exists from earnings momentum and dividend reliability, but risks include market volatility and execution challenges from recent acquisitions. The stock's current price is below the consensus target, indicating room for growth if quarterly results meet expectations.
ResMed (RMD) trades at $230.91, up 2.18% today, with a bullish technical signal and strong fundamentals. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $2.68. Revenue grew to $5.15B in 2025, with a net income margin of 26.94%. Analyst consensus is a buy, with a $242.70 price target. Recent news highlights EPS growth targets of 12%-14% and participation in investor conferences.
Outlook is positive due to robust earnings growth and market share gains, but risks include competitive pressures and regulatory investigations. The stock offers upside to the consensus target, supported by institutional buying and solid cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
